| Amount | Holding |
|---|---|
| 4.63% | UnitedHealth Group Inc |
| 4.15% | Merck & Co Inc |
| 3.78% | Abbott Laboratories |
| 3.57% | Novo Nordisk A/S B |
| 3.52% | Vertex Pharmaceuticals Inc |
| 3.40% | AstraZeneca PLC |
| 3.23% | Roche Holding AG Dividend Right Cert. |
| 3.08% | Danaher Corp |
| 2.64% | Amgen Inc |
| 2.46% | Zoetis Inc Class A |
| 2.45% | Thermo Fisher Scientific Inc |
| 2.22% | Johnson & Johnson |
| 2.18% | CVS Health Corp |
| 2.05% | Boston Scientific Corp |
| 1.88% | Lonza Group Ltd |
| 1.83% | Intuitive Surgical Inc |
| 1.80% | DexCom Inc |
| 1.73% | Immunomedics Inc |
| 1.73% | Centene Corp |
| 1.73% | Seattle Genetics Inc |
| 1.60% | Bio-Rad Laboratories Inc |
| 1.49% | Edwards Lifesciences Corp |
| 1.45% | Genmab A/S |
| 1.41% | UCB SA |
| 1.32% | Anthem Inc |
Expense Ratio Rating
4 /10
Expense Rating
0 /10
Market Score
0 /10
Category Score
0 /10
Market Size
0 /10
$LHCAX Alternatives
11%
FI Score
- lhcax
- Mutual Fund
- Sector Equity
- Healthcare
Lord Abbett Health Care Fund Class A
Expenses: 1.03% (Better than 0% of similar funds)
This is a bad choice for a Healthcare Sector Equity fund. See why ยป